Table 2. Univariate and multivariate RFS and OS analysis of 282 patients in the entire cohort.
| Variables | RFS | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Age, years (≥60 vs. <60) | 1.195 (0.750–1.905) | 0.455 | 3.266 (1.894–5.631) | <0.001 | 3.086 (1.585–6.024) | 0.001 | |||||
| Gender (male vs. female) | 1.079 (0.676–1.723) | 0.748 | 1.604 (0.928–2.774) | 0.087 | |||||||
| Smoking history (ever vs. never) | 1.145 (0.692–1.894) | 0.589 | 1.736 (0.958–3.147) | 0.046 | 1.767 (1.016–3.077) | 0.044 | |||||
| Radiologic component (solid vs. part-solid) | 4.871 (3.057–7.759) | <0.001 | 3.215 (1.678–6.173) | <0.001 | 5.986 (3.474–10.31) | <0.001 | 3.759 (1.590–8.850) | 0.003 | |||
| Surgical procedure (LOB vs. SEG/WED) | 3.221 (1.401–7.404) | 0.08 | 1.054 (0.389–2.858) | 0.92 | |||||||
| Histologic subtype (high vs. intermediate) | 1.314 (0.549–3.146) | 0.490 | 2.582 (0.920–7.246) | 0.007 | 0.330 | ||||||
| Pathological tumor size (T1b vs. T1a) | 1.314 (0.676–2.553) | 0.463 | 1.502 (0.682–3.304) | 0.382 | |||||||
| N stage (N1–2 vs. N0) | 5.101 (2.602–10.00) | <0.001 | 3.215 (1.934–5.319) | <0.001 | 5.110 (2.541–10.28) | <0.001 | 3.257 (1.799–5.882) | <0.001 | |||
| VPI (present vs. absent) | 1.887 (0.971–3.668) | 0.020 | 0.495 | 2.047 (0.985–4.256) | 0.015 | 0.566 | |||||
| LVI (present vs. absent) | 2.387 (1.103–5.168) | 0.002 | 0.512 | 3.452 (1.511–7.891) | <0.001 | 0.401 | |||||
| EGFR mutation (yes vs. no) | 0.899 (0.551–1.468) | 0.664 | 0.468 (0.263–0.832) | 0.005 | 0.121 | ||||||
RFS, recurrence-free survival; OS, overall survival; LOB, lobectomy; SEG, segmentectomy; WED, wedge; VPI, visceral pleural invasion; LVI, lymphovascular invasion; EGFR, epidermal growth factor receptor.